These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3263156)

  • 1. Limitation of complement activation by perfluorocarbon emulsions: superiority of lecithin-emulsified preparations.
    Hammerschmidt DE; Vercellotti GM
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):431-8. PubMed ID: 3263156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis.
    Vercellotti GM; Hammerschmidt DE; Craddock PR; Jacob HS
    Blood; 1982 Jun; 59(6):1299-1304. PubMed ID: 7082830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Side reaction caused by the perfluorocarbon emulsions in intravenous infusion to experimental animals.
    Sedova LA; Kochetygov NI; Berkos MV; Pjatowskaja NN
    Artif Cells Blood Substit Immobil Biotechnol; 1998 Mar; 26(2):149-57. PubMed ID: 9564433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of complement by Fluosol attributable to the pluronic detergent micelle structure.
    Ingram DA; Forman MB; Murray JJ
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):456-61. PubMed ID: 7504138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interfacial properties as stability predictors of lecithin-stabilized perfluorocarbon emulsions.
    Yoon JK; Burgess DJ
    Pharm Dev Technol; 1996 Dec; 1(4):333-41. PubMed ID: 9552317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A second-generation blood substitute (perfluorodichlorooctane emulsion) does not activate complement during an ex vivo circulation model of bypass.
    Rosoff JD; Soltow LO; Vocelka CR; Schmer G; Chandler WL; Cochran RP; Kunzelman KS; Spiess BD
    J Cardiothorac Vasc Anesth; 1998 Aug; 12(4):397-401. PubMed ID: 9713726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A system establishment compatibility profiles for artificial oxygen carriers and other substances.
    Dinkelmann S; Röhlke W; Meinert H; Northoff H
    Artif Cells Blood Substit Immobil Biotechnol; 2001 Jan; 29(1):57-70. PubMed ID: 11280685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of perfluorocarbon blood substitutes determined by sedimentation field-flow fractionation.
    Yang FS; Caldwell KD; Giddings JC; Astle L
    Anal Biochem; 1984 May; 138(2):488-94. PubMed ID: 6742424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a novel perfluorocarbon emulsion on neutrophil chemiluminescence in human whole blood in vitro.
    Edwards CM; Lowe KC; Röhlke W; Geister U; Reuter P; Meinert H
    Artif Cells Blood Substit Immobil Biotechnol; 1997 May; 25(3):255-60. PubMed ID: 9167840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The elimination peculiarities of perfluorocarbon emulsions stabilized with egg yolk phospholipid.
    Putyatina TK; Aprosin UD; Afonin NI
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):1281-5. PubMed ID: 7849934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical oxygen transport using perfluorochemicals.
    Kaufman RJ
    Biotechnology; 1991; 19():127-62. PubMed ID: 1786469
    [No Abstract]   [Full Text] [Related]  

  • 12. Perfluorodecalin emulsion tested for biocompatibility in macrophages by means of a magnetometric method.
    Koester M; Lutz J; Augustin AJ; Meinert H
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(4):1231-6. PubMed ID: 7849927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation by artificial blood substitute Fluosol: in vitro and in vivo studies.
    Hong F; Shastri KA; Logue GL; Spaulding MB
    Transfusion; 1991 Sep; 31(7):642-7. PubMed ID: 1909821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Fluosol-DA infusion on the complement activation and on the blood level of histamine in man.
    Fukushima K; Nakamura M; Hinuma K
    Prog Clin Biol Res; 1983; 122():291-8. PubMed ID: 6878373
    [No Abstract]   [Full Text] [Related]  

  • 15. Stable perfluorocarbon emulsions using XMO-10 as surfactant: potential oxygen-carrying plasma expanders.
    Jing N; Cooper BA
    Biomater Artif Cells Artif Organs; 1990; 18(1):107-17. PubMed ID: 2334810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxygen solubility, rheology and hemodynamics of perfluorocarbon emulsion blood substitutes.
    Millard RW
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(2):235-44. PubMed ID: 8087245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A perfluorochemical emulsion as an oxygen carrier.
    Yokoyama K; Suyama T; Okamoto H; Watanabe M; Ohyanagi H; Saitoh Y
    Artif Organs; 1984 Feb; 8(1):34-40. PubMed ID: 6703924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of cardioplegic protection with a lecithin-based perfluoroadamantane emulsion.
    Menasch P; Grousset C; Mouas C; Moore RE; Piwnica A
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):607-16. PubMed ID: 3179492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The initial response of blood leukocytes to incubation with perfluorocarbon blood substitute emulsions.
    McDonagh PF; Wilson DS
    Artif Cells Blood Substit Immobil Biotechnol; 1995; 23(3):439-47. PubMed ID: 7493065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biocompatibility studies with a novel perfluorochemical emulsion.
    Bollands AD; Lowe KC; Sharma SK; Davis SS
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):451-3. PubMed ID: 3179482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.